Frankfurt - Delayed Quote EUR

Ascelia Pharma AB (7ZA.F)

0.2805

-0.0455

(-13.96%)

As of 8:03:30 AM GMT+2. Market Open.

Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission

MALMÖ, SE / ACCESS Newswire / May 16, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q1 for 2025 (January - March), which is now available on the company's website: Financial Reports - ASCELIA ...

ACCESS Newswire 6 hours ago

ACE-TO1.ST

ACE.ST
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025

MALMÖ, SE / ACCESS Newswire / May 7, 2025 / Ascelia Pharma (STO:ACE) - Today, on 7 May 2025, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. Resolution on adoption of accounts and allocation ...

ACCESS Newswire 8 days ago

ACE-TO1.ST

ACE.ST
Change in Number of Shares and Votes in Ascelia Pharma AB

MALMÖ, SE / ACCESS Newswire / April 30, 2025 / Ascelia Pharma (STO:ACE) During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the exercise of warrants series TO 1 issued in the rights ...

ACCESS Newswire 16 days ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION ...

ACCESS Newswire 30 days ago

ACE-TO1.ST

ACE.ST
Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion

MALMÖ, SE / ACCESS Newswire / April 11, 2025 / Ascelia Pharma (STO:ACE): The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Ascelia Pharma ...

ACCESS Newswire last month

ACE-TO1.ST

ACE.ST
Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology

MALMÖ, SE / ACCESS Newswire / April 8, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the publication of a scientific article ...

ACCESS Newswire last month

ACE-TO1.ST

ACE.ST
Notice of Annual General Meeting in Ascelia Pharma AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April 4, 2025 / Ascelia Pharma (STO:ACE) - The shareholders ...

ACCESS Newswire last month

ACE-TO1.ST

ACE.ST
Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference

MALMÖ, SE / ACCESS Newswire / April 4, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the abstract titled ‘Burden ...

ACCESS Newswire last month

ACE-TO1.ST

ACE.ST
The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION ...

ACCESS Newswire last month

ACE-TO1.ST

ACE.ST
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025

MALMÖ, SE / ACCESS Newswire / March 18, 2025 /Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) , a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Company has received final minutes from ...

ACCESS Newswire last month

ACE-TO1.ST

ACE.ST
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025

MALMÖ, SE / ACCESS Newswire / February 25, 2025 /Ascelia Pharma (STO:ACE) Today, on 25 February 2025, an extraordinary general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. Resolution on (A) employee option ...

ACCESS Newswire 2 months ago

ACE-TO1.ST

ACE.ST
Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB

Ascelia Pharma (STO:ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 7 May 2025 has been appointed. In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the members ...

ACCESS Newswire 2 months ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma AB (FRA:7ZA) (Q4 2024) Earnings Call Highlights: Strategic Advances and ...

Ascelia Pharma AB (FRA:7ZA) reports successful Phase 3 completion for Orviglance and outlines plans for NDA submission amid financial and regulatory challenges.

GuruFocus.com 3 months ago

7ZA.F
-13.96%
Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study

MALMÖ, SWEDEN / ACCESS Newswire / February 7, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today published its Q4 and Full Year Report for 2024 (January - December), which is now available on the company's website: https://www.ascelia.com/ir-media/financial-reports/ ...

ACCESS Newswire 3 months ago

ACE-TO1.ST

ACE.ST
Notice of Extraordinary General Meeting in Ascelia Pharma AB

Ascelia Pharma (STO:ACE) The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797, are hereby invited to the extraordinary general meeting (Sw. extra bolagsstämma) to be held at the premises of Setterwalls Advokatbyrå AB at Stortorget 23 in Malmö ...

ACCESS Newswire 3 months ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting

MALMÖ, SE / ACCESSWIRE / January 27, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two oral presentations and one scientific ...

ACCESS Newswire 3 months ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma Patent Granted in China for Second Generation Orviglance

MALMÖ, SWEDEN / ACCESSWIRE / December 23, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Chinese patent authorities ...

ACCESS Newswire 4 months ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025

Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abstracts with clinical data from the SPARKLE Phase 3 study with Orviglance have been accepted as an ...

ACCESS Newswire 4 months ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting

MALMÖ, SE / ACCESSWIRE / December 2, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today presents the primary results from the Orviglance® phase 3 SPARKLE Study as an oral presentation at the world's largest radiology conference, ...

ACCESS Newswire 5 months ago

ACE-TO1.ST

ACE.ST
Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program

MALMÖ, SWEDEN / ACCESSWIRE / November 22, 2024 / Ascelia Pharma (STO:ACE) The board of directors of Ascelia Pharma AB ("Ascelia Pharma") has on 22 November 2024 resolved to convert 26,310 series C shares into ordinary shares for delivery of shares ...

ACCESS Newswire 5 months ago

ACE-TO1.ST

ACE.ST

Performance Overview

Return	7ZA.F	OMX Stockholm 30 Index (^OMX)
YTD	+44.59%	+2.58%
1-Year	-65.16%	-2.36%
3-Year	-85.27%	+27.07%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ascelia Pharma AB (7ZA.F)

Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025

Change in Number of Shares and Votes in Ascelia Pharma AB

Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1

Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion

Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology

Notice of Annual General Meeting in Ascelia Pharma AB

Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference

The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025

Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025

Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025

Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB

Ascelia Pharma AB (FRA:7ZA) (Q4 2024) Earnings Call Highlights: Strategic Advances and ...

Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study

Notice of Extraordinary General Meeting in Ascelia Pharma AB

Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting

Ascelia Pharma Patent Granted in China for Second Generation Orviglance

Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025

Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting

Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program

Performance Overview